|
INDUCE-3: A randomized, double-blind study of GSK3359609 (GSK609), an inducible T-cell co-stimulatory (ICOS) agonist antibody, plus pembrolizumab (PE) versus placebo (PL) plus PE for first-line treatment of PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). |
|
|
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline/Novartis; Merck; Pfizer |
Consulting or Advisory Role - Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Merck; Novartis |
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst) |
|
|
Honoraria - Axess Oncology; Bristol-Myers Squibb; Intellisphere; Intellisphere; Ipsen; Ipsen |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Stock and Other Ownership Interests - GI biome; GI cell |
Honoraria - AstraZeneca; AstraZeneca; Merck; Roche |
Consulting or Advisory Role - AstraZeneca; Merck; Roche; Yuhan |
|
|
|
Consulting or Advisory Role - ALX Oncology; Ascendis Pharma; Bayer; BiolineRx; Bristol-Myers Squibb; Debiopharm Group; Dynavax Technologies; Merck; MSD; Regeneron; Sanofi |
|
|
Employment - Warwickshire Head and Neck Clinic |
Leadership - Warwickshire Head and Neck Clinic; Warwickshire Head and Neck Clinic (I) |
Stock and Other Ownership Interests - Warwickshire Head and Neck Clinic |
|
Speakers' Bureau - Merck; MSD; Sanofi Pasteur |
Research Funding - AstraZeneca; GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); MSD (Inst); Sanofi Pasteur (Inst); Silence Therapeutics (Inst) |
Travel, Accommodations, Expenses - Merck; MSD; Sanofi Pasteur |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline |
|
|
No Relationships to Disclose |
|
|
Employment - GlaxoSmithKline; Humana Pharmacy (I) |
Stock and Other Ownership Interests - CVS (I) |
|
|
Employment - Bristol-Myers Squibb; GlaxoSmithKline; PAREXEL |
Stock and Other Ownership Interests - Bristol-Myers Squibb; GlaxoSmithKline |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; GlaxoSmithKline; PAREXEL |
|
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline |
|
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline |
Travel, Accommodations, Expenses - GlaxoSmithKline |
|
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline |
|
Catherine Elizabeth Ellis |
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline |
|
|
Employment - GlaxoSmithKline |
Leadership - GlaxoSmithKline |
Stock and Other Ownership Interests - Bristol-Myers Squibb; GlaxoSmithKline |
Research Funding - GlaxoSmithKline |
Patents, Royalties, Other Intellectual Property - AstraZeneca; GlaxoSmithKline |
Travel, Accommodations, Expenses - GlaxoSmithKline |
|
|
Employment - GlaxoSmithKline |
|
Stock and Other Ownership Interests - GlaxoSmithKline; Imugene |
|
|
Research Funding - Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Merck; Regeneron |
Travel, Accommodations, Expenses - Merck |